Today: 15 May 2026
AppLovin stock price rises again as UBS trims target and earnings loom
10 February 2026
2 mins read

AppLovin stock price rises again as UBS trims target and earnings loom

New York, Feb 10, 2026, 17:24 ET — Trading after hours

  • AppLovin climbed 2.7% to $472.92 Tuesday, notching a second straight day of gains.
  • UBS trimmed its price target but stuck with a Buy, pointing to ad results from AppLovin’s Axon system.
  • The company will announce its quarterly results after the U.S. market shuts on Wednesday.

AppLovin Corp (APP.O) climbed 2.7% to $472.92 in after-hours action on Tuesday, building on a two-day rally before its quarterly earnings. Earlier, shares moved between $462.13 and $479.67, with roughly 6.1 million shares traded during regular hours.

Timing’s a factor here. AppLovin is set to deliver results after Wednesday’s close, and lately the stock’s been reacting sharply to a stream of analyst notes and quick-fire responses, beyond just moves in the broader market.

UBS cut its price target on AppLovin to $686 from $840 on Tuesday, sticking with its Buy call. The bank cited stronger fourth-quarter ad budgets and improved “return on ad spend” connected to AppLovin’s Axon 2.0. UBS flagged rising competitive threats, mentioning Meta’s push back into gaming ads and potential longer-term disruption from Alphabet’s Project Genie. As for Unity, UBS described its progress as more restrained. TipRanks

The rally actually kicked off the previous day. On Monday, shares soared over 13% after CapitalWatch took to social media with a correction and apology, stating it was “formally retracting” certain allegations against shareholder Tang Hao. An internal probe had determined its claims linking him to criminal groups failed the outlet’s standards. CapitalWatch added it held no financial stake in AppLovin, and said the retraction wouldn’t alter its broader position. AppLovin, for its part, had sent a cease-and-desist letter last month, calling for the withdrawal. Investopedia

Jefferies’ James Heaney is sticking with his Buy call and $860 target, shrugging off the stock’s 39% slide so far this year. On Monday, Heaney called it “a great buying opportunity,” downplaying concerns tied to CloudX, Meta Audience Network, and Google Genie as “overblown risks.” Heaney sees a “significant revenue beat” for the fourth quarter, according to his analysis. Investing.com

AppLovin, which provides software for app developers and advertisers to manage ad buying and placement, has positioned Axon as its solution for automating targeting and bidding. Investors want to see proof that ad performance remains solid—and that e-commerce spending has room to keep growing.

AppLovin plans to report both its fourth-quarter and full-year 2025 earnings once U.S. trading wraps up on Feb. 11, the company said. CEO Adam Foroughi and CFO Matthew Stumpf will lead a webcast at 5 p.m. ET.

But there’s risk on both sides. Disappointing results, or even a cautious tone—especially after bullish research has already shifted expectations—could see the move reverse just as quickly, sending shares right back where they started in a week.

Sentiment shocks remain a core risk here. The stock’s history includes sudden swings after external commentary. Competitive pressure isn’t letting up either, with larger platforms and fresh players continually entering the field.

Wednesday’s report is up next, with the earnings call tone likely to matter just as much. Traders are set to parse guidance, watching for concrete signs of how AppLovin aims to hold advertiser interest straight through 2026.

Stock Market Today

  • Apollo Global Management to Pay $0.5625 Dividend; Ex-Dividend Date Approaches
    May 15, 2026, 3:43 PM EDT. Apollo Global Management (NYSE:APO) will trade ex-dividend in three days, with a dividend of US$0.5625 per share payable on May 29. Investors must own shares by May 19 to qualify. Last year, Apollo paid a total of US$2.25 in dividends, yielding 1.7% at the current share price of US$135.52. The company has shown strong earnings growth of 35% annually over five years but paid out 107% of income as dividends last year, suggesting potential sustainability concerns. Dividend growth averaged 3.0% annually over the past decade, indicating moderate increase despite rapid earnings expansion. Investors should weigh Apollo's growth against its high payout ratio when considering its dividend prospects.

Latest articles

AT&T’s Starlink Defense: Verizon, T-Mobile Join Rare Satellite Push to Kill Dead Zones

AT&T’s Starlink Defense: Verizon, T-Mobile Join Rare Satellite Push to Kill Dead Zones

15 May 2026
AT&T, Verizon, and T-Mobile announced plans to jointly build a satellite-based network to eliminate U.S. wireless dead zones, aiming to connect ordinary phones directly to satellites. The move follows the FCC’s approval of EchoStar’s $40 billion spectrum sale to SpaceX and AT&T. The carriers have an agreement in principle but have not finalized terms. AT&T reported $31.5 billion in Q1 revenue and $126.4 billion in net debt.
Ambev Stock Faces Reality Check After Brazil Beer Boom and UBS Sell Call

Ambev Stock Faces Reality Check After Brazil Beer Boom and UBS Sell Call

15 May 2026
Ambev’s São Paulo shares fell 0.25% to 15.73 reais Friday, despite UBS raising its target price but maintaining a Sell rating. First-quarter profit rose 2.1% to 3.89 billion reais, with Brazil Beer volumes hitting a record and net revenue up 9.6%. Cash flow surged 162.5% to 3.16 billion reais. Consolidated cash cost of goods sold per hectoliter climbed 8.5%.
Pfizer Inc Looks to India for Growth—But Proof Remains Elusive for Investors

Pfizer Inc Looks to India for Growth—But Proof Remains Elusive for Investors

15 May 2026
Pfizer is increasing investment in India for cancer drugs, obesity treatments, and vaccines as it seeks growth beyond COVID-era sales. The company reported Q1 revenue of $14.5 billion, up 5%, but expects a $1.5 billion hit this year from generic competition. Shares fell 1.8% to $25.29 in New York trading. In Europe, Pfizer won expanded approval for its hemophilia drug Hympavzi.
BigBear.ai Stock Drops as Investors Question Defense-AI Growth

BigBear.ai Stock Drops as Investors Question Defense-AI Growth

15 May 2026
BigBear.ai shares fell about 5% to $4.16 Friday afternoon after reporting flat first-quarter revenue of $34.4 million and a wider adjusted EBITDA loss of $9.9 million. Backlog rose 14% to $281.9 million, boosted by a $53 million classified contract. The company kept its 2026 revenue forecast at $135 million to $165 million. Gross margin improved to 34.0% from 21.3% a year earlier.
KKR stock steadies near $107 as investors await CFO update after 4% surge
Previous Story

KKR stock steadies near $107 as investors await CFO update after 4% surge

Marriott (MAR) stock jumps toward record high on luxury travel demand and credit-card fee outlook
Next Story

Marriott (MAR) stock jumps toward record high on luxury travel demand and credit-card fee outlook

Go toTop